¶ Alexander Disease Genetic Variants
Alexander Disease Genetic Variants represents an important genetic factor in neurodegenerative disease research. This page provides comprehensive information about its role in disease mechanisms, genetic associations, and therapeutic implications.
Alexander disease (AD) is a rare astrogliopathy caused by mutations in the GFAP gene, leading to accumulation of Rosenthal fibers in astrocytes throughout the central nervous system. It is classified as a leukodystrophy because it primarily affects white matter. This page summarizes the key genetic variants associated with Alexander disease, their molecular mechanisms, clinical implications, and therapeutic relevance.
Alexander disease presents in two main forms:
- Infantile form (70% of cases): Onset before age 2, rapid progression
- Adult form (30% of cases): Slower progression, variable presentation
Clinical features include:
- Developmental delay and regression
- Macrocephaly
- Seizures
- Ataxia
- Spasticity
- Bulbar signs (dysphagia, dysarthria)
The disease is caused by dominant, gain-of-function mutations in GFAP, an intermediate filament protein expressed primarily in astrocytes.
The GFAP gene on chromosome 17q21 encodes an intermediate filament protein that is a key component of the astrocytic cytoskeleton. Over 150 pathogenic variants have been identified, including:
- Missense mutations: Most common, typically affecting conserved residues
- Splice site mutations: Lead to aberrant GFAP isoforms
- Small deletions/insertions: Frameshift mutations
- Splice site variants in intron 8: Common hotspot for mutations
Key features of GFAP variants:
- Inheritance: Autosomal dominant (de novo in most cases)
- Penetrance: Near 100% for symptomatic mutations
- Genotype-phenotype: Correlation between mutation position and age of onset
- Somatic mosaicism: Rare cases with milder disease
| Region |
Common Mutations |
Phenotype |
| Exon 1 |
R79C, R79H |
Infantile |
| Exon 4 |
R239C, R239H |
Variable |
| Exon 6 |
D416N, K420E |
Adult |
| Exon 8 |
P496S, R416W |
Variable |
| Intron 8 |
c.806+1G>A |
Adult |
GFAP mutations lead to disease through:
- Protein aggregation: Mutant GFAP forms insoluble aggregates
- Rosenthal fiber formation: Accumulation of GFAP with stress proteins
- Astrocyte dysfunction: Impaired potassium buffering, glutamate uptake
- Myelin abnormalities: Secondary oligodendrocyte dysfunction
- Inflammation: Activation of astrocytic inflammatory pathways
- Supportive care: Physical therapy, seizure management, nutritional support
- Corticosteroids: May slow progression in some cases
- Speech and occupational therapy: Maintain function
- GFAP silencing: Antisense oligonucleotides to reduce mutant GFAP
- Gene therapy: AAV-mediated GFAP knockdown
- Protein aggregation inhibitors: Small molecules to prevent Rosenthal fiber formation
- Mesenchymal stem cell transplantation: Potential therapeutic approach
Active research includes:
- Natural history studies
- Biomarker development (GFAP in CSF/plasma)
- ASO therapeutic approaches
- Brenner et al., GFAP mutations in Alexander disease (2001)
- Quinlan et al., GFAP aggregation and Alexander disease (2007)
- Messing, Alexander disease: GFAP and neurodegeneration (2018)
- Parmar et al., Adult-onset Alexander disease (2020)
- Gene Reviews: Alexander Disease
- Wang et al., GFAP ASO therapy in animal models (2020)
- International Alexander Disease Foundation